Inovio Pharmaceuticals (NASDAQ: INO)
Inovio Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Inovio Pharmaceuticals Company Info
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
News & Analysis
This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?
Can the biotech succeed after a string of failures?
Why Inovio Pharmaceuticals' Shares Jumped on Thursday
The company will present an abstract for its Ebola vaccine booster this month.
Why Shares of Inovio Pharmaceuticals Were Down Tuesday
The biotech stock, still reeling from a failed clinical trial, hit a 52-week low.
2 Stocks to Sell or Remove From Your Watchlist in 2023
Both stocks soared during the coronavirus vaccine race, but their time has passed.
Why Inovio Pharmaceuticals Stock Zoomed Nearly 6% Higher Today
The biotech is ceasing its internally funded efforts to develop a heterologous coronavirus booster.
Why Inovio Pharmaceuticals' Shares Jumped 17.31% on Monday
The stock jumped Monday despite no news from the company.
1 Green Flag and 1 Red Flag For Inovio Pharmaceuticals
Can the company still count on its coronavirus-related efforts?
Why Inovio Pharmaceuticals Is Gaining Today
Its newly announced cost-saving measures are getting a warm reception.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.